Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
{{output}}
Introduction: Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded i... ...
